GlassScriptPhysician profile
Sonal Dholakia
NPI 1164452876
$6,935.44
in general payments reported to CMS, 2019-2025
31 companies · $2,177 in 2025
The $2,177 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $600 · 2021: $867 · 2022: $724 · 2023: $1,005 · 2024: $1,150 · 2025: $2,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,332.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,120.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,048.28 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $555.57 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $449.30 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $382.77 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $271.21 | 2019-2025 | Arexvy, Shingrix |
| Pfizer INC. | $253.41 | 2020-2025 | |
| Dexcom, INC. | $236.93 | 2022-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $167.89 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.13 | 2019-2025 | Jardiance |
| Amgen INC. | $153.75 | 2023-2025 | Repatha, Repatha, Otezla |
| Ethicon US, LLC | $152.57 | 2020-2022 | |
| Abbvie INC. | $139.84 | 2024 | |
| Eisai INC. | $125.57 | 2025 | |
| Currax Pharmaceuticals LLC | $94.40 | 2023-2025 | Onzetra Xsail, Contrave |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $80.33 | 2025 | Apretude |
| Inspire Medical Systems, INC. | $67.37 | 2023-2025 | Inspire |
| Merck Sharp & Dohme LLC | $59.48 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $56.32 | 2020-2021 | |
| Genentech USA, INC. | $50.32 | 2019-2021 | |
| Gilead Sciences, INC. | $49.30 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.55 | 2022 | |
| Dynavax Technologies Corporation | $38.30 | 2019-2025 | Heplisav-B |
| Sanofi Pasteur INC. | $38.14 | 2023 | |
| Vivus LLC | $34.34 | 2021 | |
| Janssen Pharmaceuticals, INC | $25.00 | 2023 | Xarelto |
| Medtronic, INC. | $22.44 | 2022 | |
| Antares Pharma, INC. | $17.64 | 2021 | |
| Organon LLC | $17.20 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.04 | 2023 | Quviviq |
| Theracosbio, LLC | $4.99 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonal Dholakia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.